News summary

Obesity drugs lowered systolic pressure 4.9 mmHg across 37 trials

Source: Longevity Docs News • Published: 28 Oct 2026, 00:00

Summarized by Masters of Longevity from Longevity Docs News.

Meta-analysis found a 4.9 mmHg systolic drop across 37 phase 3 trials.

Obesity drugs lowered systolic pressure 4.9 mmHg across 37 trials
Key Takeaways
  • The study pooled 50,171 adults with overweight or obesity.
  • Each 1% weight loss was linked to 0.37 mmHg lower systolic pressure.
  • The between-trial link is observational and not proven causal.
Read the full article at Longevity Docs News ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.